Across TCGA pan-cancer cohorts, NANOGP6 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of NANOGP6’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where NANOGP6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NANOGP6 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRC, THCA, and STAD are the cancer types where NANOGP6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NANOGP6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	+0.053	<.001	10	view →
THCA	Female	All	−0.016	.037	2	view →
STAD	Male	II,III,IV	+0.120	.042	1	view →
LUAD	All	II,III,IV	+0.028	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NANOGP6 RNA expression & survival · all NANOGP6 data types